Velenosi TJ, Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol 10(8):1131–1143

Article  Google Scholar 

Agarwal R, Cronin RE (1994) Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis janv 23(1):47–51

Article  Google Scholar 

De Bock V, Verbeelen D, Maes V, Sennesael J (1989) Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 4(7):635–639

Google Scholar 

Vincent HH, Vos MC, Akçahuseyin E, Goessens WH, van Duyl WA, Schalekamp MA (1993) Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif 11(2):99–107

Article  Google Scholar 

Pea F, Viale P, Pavan F, Furlanut M (2007) Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 46(12):997–1038

Article  Google Scholar 

Manley HJ, Aweh G, Weiner DE, Jiang H, Miskulin DC, Johnson D et al (2020) Multidisciplinary medication therapy management and hospital readmission in patients undergoing maintenance dialysis: a retrospective cohort study. Am J Kidney Dis 76(1):13–21

Article  Google Scholar 

Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D et al (2018) Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol 84(12):2811–2823

Article  Google Scholar 

Pai AB, Cardone KE, Manley HJ, St. Peter WL, Shaffer R, Somers M et al (2013) Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach. CJASN 8(11):1988–1999

Article  Google Scholar 

Roux-Marson C, Baranski JB, Fafin C, Exterman G, Vigneau C, Couchoud C et al (2020) Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease. BMC Geriatr 20. Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057617/

2012 DOPPS Annual Report. Disponible sur: https://www.dopps.org/annualreport/

Cotoi L, Borcan F, Sporea I, Amzar D, Schiller O, Schiller A et al (2020) Thyroid pathology in end-stage renal disease patients on hemodialysis. Diagnostics (Basel) 10(4):E245

Article  Google Scholar 

https://www.vidal.fr/medicaments.html

Information Conseil Adaptation Rénale ICAR. http://www.sitegpr.com/ last accessed in Jun 2017

WHOCC - ATC/DDD Index. Disponible sur: https://www.whocc.no/atc_ddd_index/

Maruyama T, Takashima H, Abe M (2020) Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. Expert Opin Pharmacother 21(10):1219–1240

Sreedhara R, Itagaki I, Lynn B, Hakim RM (1995) Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 25(4):555–563

Article  Google Scholar 

You AS, Sim JJ, Kovesdy CP, Streja E, Nguyen DV, Brent GA et al (2019) Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrol Dial Transplant 34(12):2095–2104

Article  Google Scholar 

Leung KCW, MacRae JM (2019) Anticoagulation in CKD and ESRD. J Nephrol 32(5):719–731

Article  Google Scholar 

Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F et al (2020) Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. EP Europace 22(3):496–505

Article  Google Scholar 

Belley-Cote EP, Eikelboom JW (2020) Anticoagulation for stroke prevention in patients with atrial fibrillation and end-stage renal disease-first, do no harm. JAMA Netw Open 3(4):e202237

Article  Google Scholar 

Goel N, Jain D, Haddad DB, Shanbhogue D (2020) Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences. J Stroke 22(3):306–316

Article  Google Scholar 

Waddy SP, Ward JB, Becerra AZ, Powers T, Fwu CW, Williams KL et al (2019) Epilepsy and antiseizure medications increase all-cause mortality in dialysis patients in the United States. Kidney Int 96(5):1176–1184

Article  Google Scholar 

Sedation, an unpleasant, undesirable and potentially dangerous side‐effect of many psychotropic drugs - Bourin - 2004 - human psychopharmacology: clinical and experimental. Wiley Online Library. Disponible sur: https://doi.org/10.1002/hup.561

Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK (2019) Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Intern Med J 49(7):838–842

Article  Google Scholar 

Weir MA, Herzog CA (2018) Beta blockers in patients with end-stage renal disease-evidence-based recommendations. Semin Dial 31(3):219–225

Article  Google Scholar 

Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL (2018) β-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial. Clin J Am Soc Nephrol 13(4):604–611

Article  Google Scholar 

Georgianos PI, Agarwal R (2018) Blood pressure control in conventional hemodialysis. Semin Dial 31(6):557–562

Article  Google Scholar 

Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG (2014) Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 29(3):672–681

Article  Google Scholar 

Saudan P (2003) Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 18(11):2359–2363

Article  Google Scholar 

Ravis WR, Reid S, Sica DA, Tolbert DS (2005) Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 45(7):810–821

Article  Google Scholar 

Inrig JK (2010) Antihypertensive agents in hemodialysis patients: a current perspective: antihypertensive agents in hemodialysis patients. Seminars Dial 23(3):290–297

Article  Google Scholar 

Sinha AD, Agarwal R (2019) Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. CJASN 14(5):757–764

Article  Google Scholar 

Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM, Flythe J (2019) Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes. CJASN 14(1):95–102

Article  Google Scholar 

Gallagher KL (1979) Furosemide-induced ototoxicity. Ann Intern Med 91(5):744

Article  Google Scholar 

Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the retrospective evaluation and assessment of therapies in AF study | Elsevier Enhanced Reader. Disponible sur: https://reader.elsevier.com/reader/sd/pii/S0002870315004639?token=8182033DE11C9E3D109937B1FD47C3A2AAE8287E6B29296706B3A51100C8CF4412AA0185B40237B4455CF1205A708E99

Wanner C, Herzog CA, Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM et al (2018) Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 94(2):231–234

Article  Google Scholar 

Walton T, Thomas R (2010) Cardiovascular agents. Seminars Dial 23(5):480–482

Article  Google Scholar 

Bonato FOB, Canziani MEF (2017) Ventricular arrhythmia in chronic kidney disease patients. Jornal Brasileiro de Nefrologia 39(2). Disponible sur: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002017000200186

Voroneanu L, Ortiz A, Nistor I, Covic A (2016) Atrial fibrillation in chronic kidney disease. Eur J Intern Med 33:3–13

Article  Google Scholar 

Brown CDA, Windass A, Bleasby K, Lauffart B (2001) Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler 90(2):174

Google Scholar 

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C (2006) Prescription des statines en cas d’insuffisance rénale: Efficacité, tolérance et maniement chez le patient insuffisant rénal et chez le patient transplanté rénal. La Presse Médicale 35(2):219–229

Article  Google Scholar 

Heine GH, Eller K, Stadler JT, Rogacev KS, Marsche G (2020) Lipid-modifying therapy in chronic kidney disease: pathophysiological and clinical considerations. Pharmacol Therapeut 207:107459

Article  Google Scholar 

Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L et al (2019) Influence of renal function on evolocumab exposure, pharmacodynamics, and safety. Clin Pharmacol Drug Develop 8(3):281–289

Article  Google Scholar 

Desager JP, Costermans J, Verberckmoes R, Harvengt C (1982) Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 31(1):51–54

Article  Google Scholar 

Abdel Magid AM, Abbassi MM, Iskander EEM, Mohamady O, Farid SF (2017) Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis. J Comp Eff Res 6(5):413–424

Article  Google Scholar 

Evans JR, Forland SC, Cutler RE (1987) The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 27(12):994–1000

Article  Google Scholar 

Anderson P, Norbeck HE (1981) Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. Eur J Clin Pharmacol 21(3):209–214

Article  Google Scholar 

Takeda K, Nakamoto M, Yasunaga C, Nishihara G, Matsuo K, Urabe M et al (1997) Blood monitoring of bezafibrate in a chronic hemodialysis patient. Nephron 76(4):487–488

Article  Google Scholar 

Grützmacher P, Scheuermann EH, Siede W, Lang PD, Abshagen U, Radtke HW et al (1986) Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. Klin Wochenschr 64(19):910–916

Article  Google Scholar 

Gregory S, Jenkins K (2019) Managing care for people with diabetes undergoing dialysis: managing care for people with diabetes undergoing dialysis. J Renal Care 45(1):59–67

Article  Google Scholar 

Di Lullo L, Mangano M, Ronco C, Barbera V, De Pascalis A, Bellasi A et al (2017) The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes Metab Syndr 11:S295-305

Article  Google Scholar 

Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D et al (2019) Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant 34(6):923–933

Article  Google Scholar 

Marbury T (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. Clin PharmacolTherapeut 67(1):7–15

Google Scholar 

Blumenberg A, Benabbas R, Sinert R, Jeng A, Wiener SW (2020) Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic review and meta-analysis of pH and lactate as predictors of mortality in MALA. J Med Toxicol 16(2):222–229

Article  Google Scholar 

Idorn T, Knop FK, Jørgensen MB, Jensen T, Resuli M, Hansen PM et al (2015) Safety and Efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blinded, parallel group, randomized trial. Dia Care. dc151025

Keane WF, Swan SK, Grimes I, Humphries TJ (1999) Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 39(9):927–933

Article  Google Scholar 

Kliem V (1998) Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transplant 13(5):1189–1193

Article  Google Scholar 

Karol MD, Machinist JM, Cavanaugh JM (1995) Pharmacokinetics of lansoprazole in hemodialysis patients. J Clin Pharmacol 35(8):815–820